Dr méd. Antoine Leimgruber


FMH Specialist in Nuclear Medicine
FMH Specialist in Radiology
MS Physics EPFL

Work experience

since 2021 Director of Development Swiss Medical Network, Nuclear Medicine
since 2019 Co-Founder, Biopsomic SA
2015-2021 Head of Nuclear Medicine and Oncology (Hopital Riviera-Chablais)
2007-2014 Fellowships, Lausanne University Hospital, Peter MacCallum Cancer Centre, Austin Health, Center for Molecular Imaging Research & Center for Systems Biology, Harvard Medical School
2001-2006 Research Associate, Molecular Modelling Group, Swiss Institute of Bioinformatics and Ludwig Institute Lausanne
2000 Project Engineer, Picture Archiving and Communication System, Service of Radiology, Lausanne University Hospital
1998-1999 Financial mathematics consultant, Time-Steps Ltd, Zurich


2007-2015 Specialist training:
  • Hybrid imaging fellow, Department of Cancer Imaging, Peter MacCallum Cancer Centre (Prof Hicks, Melbourne)
  • Nuclear Medicine Registrar, Service of Nuclear Medicine & Ludwig Institute (Prof Rowe and Scott, Melbourne Australia)
  • Fellow, Service of Nuclear Medicine, Lausanne University Hospital (Prof Prior, Switzerland)
  • Resident, Service of Radiology, Lausanne University Hospital (Prof Schnyder, Meuli, Switzerland)
  • Postdoctoral Fellow, Center for Molecular Imaging Research & Center for Systems Biology (Prof Pittet & Weissleder, Harvard Medical School, USA)
2000-2007 Non-specialist training:
  • Lausanne University Hospital
  • Massachusetts General Hospital (Boston USA)
  • Oncology Institute of Oriental Bolivia (Santa Cruz Bolivia)
  • Ambulatorio Dr David Espinoza Rojas (Nueva Esparta, Venezuela)


  • Swiss Medical Association (FMH)
  • Vaud State Medical Society (SVM)
  • Swiss Society of Nuclear Medicine (SSNM)
  • Swiss Radiology Society (SSR) European Neuroendocrine Tumor Society
  • Australian and New Zealand Society of Nuclear Medicine (ANZSNM)
  • Radiological Society of North America (RSNA)
  • European Neuroendocrine Tumor Society (ENETS)
  • Vaud State Academic Society

  • Lobb RJ, van Amerongen R, Wen Wen S, Wong CSF, Wiegmans AP, Hstie M, Norris E, Siva S, Everitt S, Fong K, Gorman J, Leimgruber A and Möller A, An epithelial-to-mesenchymal transition induced multi-protein exosome signature prognosticates patient outcome in non-small cell lung cancer, in prep.
  • Gatta R, Depeursinge A, Ratib O, Michielin O, Leimgruber A, Integrating radiomics into holomics for personalised oncology: from algorithms to bedside, European Radiology Exp, 2020 Feb 07,4(11) - ~10 citations
  • Leimgruber A, Hickson K, Lee ST, Gan HK, Cher LM, Sachinidis JLO, O’Keefe GJ, Scott AM, Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse, EJNMMI, 2020 Feb 5;47(1476-1485) - ~10 citations
  • Wen Wen S, Everitt SJ, Bedö J, Chabrot M, Ball DL, Solomon B, MacManus M, Hicks RJ, Möller A and Leimgruber A, Spleen volume variation in patients with locally advanced non-small cell lung cancer receiving platinum-based chemo-radiotherapy, PLoS One. 2015 Nov 24;10(11) - ~15 citations
  • Lobb RJ, Becker M, Wen Wen S, Wong CSF, Wiegmans AP, Leimgruber A, Möller A, Optimized Exosome Isolation Protocol for Cell Culture Supernatant and Human Plasma, J Extracell Vesicles. 2015 Jul 17;4 - ~800+ citations
  • Leimgruber A, Möller A, Everitt S, Chabrot M, Ball D, Solomon B, MacManus M and Hicks R, Effect of platinum-based chemoradiotherapy on cellular proliferation in bone marrow and spleen, estimated by FLT-PET/CT in patients with locally advanced non-small cell lung cancer, J Nucl Med. 2014 May 27;55(7) - ~30 citations & Alavi-Mandell award
  • Leimgruber A, Ferber M, Irving M, Hussain-Kahn H, Wieckowski S, Rufer N, Zoete V and Michielin O, TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires, PloS One. 2011;6(10) - ~20 citations
  • Gambarota G, Perazzolo C, Leimgruber A, Meuli R, Mangin P, Augsburger M and Grabherr S, Non-invasive detection of dissolved cocaine in wine bottles by magnetic resonance spectroscopy, Drug Test Anal. 2010 Sep 30.
  • Leimgruber A, Berger C, Cortez-Retamozo V, Etzrodt M, Newton A, Waterman P, Figueiredo J, Kohler R, Elpek N, Mempel T, Swirski F, Nahrendorf M, Weissleder R and Pittet M, Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle, Neoplasia. 2009 May; 11(5) - ~100 citations & journal cover
  • Derré L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A, Zoete V, Romero P, Michielin O, Speiser D and Rufer N, Structurally distinct TCRs confer similar recognition of the tumor-specific epitope NY-ESO-1157-165 by interacting with its central Met/Trp residues, Proc Natl Acad Sci U S A. 2008 Sep 30;105(39) - ~40 citations
  • Derré L, Ferber M, Touvrey C, Devevre E, Zoete V, Leimgruber A, Romero P, Michielin O, Lévy F and Speiser D, A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide, J Immunol, 2007 Dec 1;179(11) - ~30 citations
  • Leimgruber A, Ostermann S, Yeon EJ, Buff E, Maeder P, Stupp R and Meuli R, Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial, Int J Radiat Oncol Biol Phys, 2006 Mar 1;64(3) - ~40 citations
Portrait Dr méd. Antoine Leimgruber


French, English, Spanish and German (basic)


Clinique de Genolier
Route du Muids 3
1272 Genolier

T +41 22 366 94 84 aleimgruber@swissmedical.net

Download vCard